Stay updated on SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial page.

Latest updates to the SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial page
- CheckyesterdayChange DetectedThe revision label on the page updated from v3.5.4 to v3.5.5, indicating a software update to the page. This change does not alter study data or user-facing functionality.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedFooter release tag updated to Revision: v3.5.4, reflecting a new platform version for the history page. The underlying study information remains unchanged.SummaryDifference0.0%

- Check43 days agoChange DetectedThe page’s footer/application version was updated from **v3.5.2** to **v3.5.3** for the ClinicalTrials.gov interface.SummaryDifference0.0%

- Check50 days agoChange DetectedVersion 97 (2026-04-13) adds the Contacts/Locations and Study Status sections to the record history and updates the system to Revision: v3.5.2; the prior Revision: v3.5.0 was removed on 2026-03-18.SummaryDifference0.2%

- Check79 days agoChange DetectedVersion 96 (2026-03-17) updates Study Status and Contacts/Locations; Revision: v3.5.0 is added on 2026-03-18.SummaryDifference0.2%

- Check86 days agoChange DetectedFooter Revision: v3.4.3 is added and Revision: v3.4.2 is removed, indicating a site maintenance update on the history page.SummaryDifference0.0%

Stay in the know with updates to SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial page.